Timothy Finnerty v. Stiefel Laboratories, Inc.

CourtCourt of Appeals for the Eleventh Circuit
DecidedJune 30, 2014
Docket12-13947
StatusPublished

This text of Timothy Finnerty v. Stiefel Laboratories, Inc. (Timothy Finnerty v. Stiefel Laboratories, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Timothy Finnerty v. Stiefel Laboratories, Inc., (11th Cir. 2014).

Opinion

Case: 12-13947 Date Filed: 06/30/2014 Page: 1 of 29

[PUBLISH]

IN THE UNITED STATES COURT OF APPEALS

FOR THE ELEVENTH CIRCUIT ________________________

No. 12-13947 ________________________

D.C. Docket No. 1:09-cv-21871-JLK

TIMOTHY FINNERTY, Plaintiff-Appellee,

versus

STIEFEL LABORATORIES, INC., a Delaware Corporation, CHARLES W. STIEFEL,

Defendants-Appellants.

________________________

No. 12-15060 ________________________

STIEFEL LABORATORIES, INC., a Delaware Corporation, CHARLES W. STIEFEL, Case: 12-13947 Date Filed: 06/30/2014 Page: 2 of 29

No. 12-15642 ________________________

STIEFEL LABORATORIES, INC., a Delaware Corporation, CHARLES W. STIEFEL,

_________________________

Appeals from the United States District Court for the Southern District of Florida _________________________

(June 30, 2014)

Before ANDERSON, Circuit Judge, and MOODY* and SCHLESINGER,** District Judges. ____________ *Honorable James S. Moody, Jr., United States District Judge for the Middle District of Florida, sitting by designation.

**Honorable Harvey E. Schlesinger, United States District Judge for the Middle District of Florida, sitting by designation.

2 Case: 12-13947 Date Filed: 06/30/2014 Page: 3 of 29

ANDERSON, Circuit Judge:

Plaintiff Timothy Finnerty filed this lawsuit against Stiefel Laboratories, Inc.

(“SLI”) and its chief executive officer, Charles Stiefel (hereinafter jointly referred

to as “SLI”), alleging violations of § 10(b) of the Securities Exchange Act of 1934

and accompanying Rule 10b-5. The allegation is that SLI withheld material

information about preliminary merger negotiations that it was obliged to disclose.

The case was tried before a jury which returned a verdict for Finnerty. The district

court subsequently denied SLI’s renewed motion for judgment as a matter of law

and alternative motion for a new trial. SLI appeals from that denial, arguing

principally that it had no duty to disclose the merger negotiations, that the

negotiations were immaterial, and that the district court erroneously refused to give

a request to charge to the jury. For the reasons that follow, we affirm.

I. Background. 1

A. The Blackstone investment.

SLI was a privately-held pharmaceutical company controlled by the Stiefel

family from its founding in 1847 until 2009, when it merged with

GlaxoSmithKline (“GSK”). SLI took great pride in its privately-held status; the

1 In accordance with our standard of review for renewed judgment as a matter of law, we present the facts in the light most favorable to Finnerty. See SEC v. Ginsburg, 362 F.3d 1292, 1296 (11th Cir. 2004).

3 Case: 12-13947 Date Filed: 06/30/2014 Page: 4 of 29

Stiefel family brought up this fact at nearly every company meeting and impressed

upon employees their commitment to keeping SLI under the family’s control.

In August 2007, SLI announced a $500 million minority investment by The

Blackstone Group (“Blackstone”). Under the terms of the investment, Blackstone

purchased preferred shares at approximately $60,000 per share. Additionally, in

connection with the investment, Blackstone acquired the right to name one

member of SLI’s board of directors. Sometime in 2008, Blackstone named Anjan

Mukherjee, a managing director at Blackstone, to SLI’s board.

Anticipating the speculation that might result from Blackstone’s investment,

on August 9, 2007, SLI issued a press release that stated: “[SLI] . . . will continue

to be privately held, and the Stiefel family will retain control and continue to hold

a majority-share ownership of the company.” That same day, Charles Stiefel sent

an e-mail to SLI employees assuring them that “[SLI] will continue to be a

privately held company operating under my direction as Chairman, Chief

Executive Officer, and President.” A “Frequently Asked Questions” document

attached to the e-mail further informed employees:

Will [SLI] be going public? There are currently no plans for [SLI] to become a publicly traded company. Blackstone will have a defined exit arrangement with [SLI] at the end of eight years, at which point [SLI] may choose to buy back its shares or exercise other options, one of which might be an initial public offering. Senior management continues to evaluate all options when looking at the long-term financial needs of the company.

4 Case: 12-13947 Date Filed: 06/30/2014 Page: 5 of 29

B. Finnerty’s “put” election.

Finnerty worked as a sales representative for SLI from 1986 until he was

terminated on August 29, 2008, along with numerous others in a reduction of

force. As an employee, Finnerty participated in SLI’s Employee Stock Bonus Plan

(“ESBP”). Upon termination of employment, ESBP participants became entitled

to a distribution of the vested benefits in their accounts paid in the form of SLI

stock. Participants also received a “put” option on the distributed stock, which

allowed them to require SLI to buy back the stock at a fair market value during a

certain window of time.

Although Finnerty was eligible for his vested ESBP benefits after his

termination, he initially elected to defer the distribution. But in November 2008,

Finnerty received a letter from SLI announcing major changes to the ESBP.

Shortly thereafter, Finnerty received another letter reminding him of the

opportunity to take a distribution and providing him with the necessary paperwork.

Concerned about the impending changes, on January 6, 2009, Finnerty executed a

form irrevocably electing to receive his distribution of SLI stock and to “put” the

stock to SLI at the then-effective fair market value of $16,469 per share. SLI

completed this transaction on February 13, 2009.

C. The sale of SLI.

5 Case: 12-13947 Date Filed: 06/30/2014 Page: 6 of 29

Unknown to Finnerty, the Stiefel family had been exploring the possibility

of selling SLI since November of 2008. Earlier that month, Mukherjee learned that

the pharmaceutical giant Sanofi-Aventis was interested in an acquisition.

Mukherjee advised the Stiefels that they should “either sell [SLI] right now or wait

five years,” and he estimated that the acquisition price could be as high as “3–5

times sales,” with the price that Blackstone paid ($60,000 per share) as the floor.

On November 26, 2008, Charles Stiefel met with his sons and they decided to

“move on” the sale.

On December 8, 2008, a team from Blackstone Advisory Services, an

affiliate of Blackstone, presented to the Stiefels a marketing strategy and timeline

for pursuing a sale, including a list of potential acquirers and a valuation analysis.

The analysis suggested that the potential acquisition price could be in the range of

$2.25 to $4 billion (around 2.5 to 4.5 times revenue). Later that month, Charles

Stiefel met with the chief executive officer of Sanofi-Aventis to discuss how the

two companies could operate together. No discussion of prices or terms took place

at this meeting. Thereafter, around December 30, 2008, SLI hired Blackstone

Advisory Services to advise on a potential sale.

In January 2009, SLI executed a confidentiality agreement with Sanofi-

Aventis and contacted several other pharmaceutical companies to gauge their

interest.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Armando Oliveros
275 F.3d 1299 (Eleventh Circuit, 2001)
Glenn J. Conroy v. Abraham Chevrolet-Tampa, Inc.
375 F.3d 1228 (Eleventh Circuit, 2004)
Mizzaro v. Home Depot, Inc.
544 F.3d 1230 (Eleventh Circuit, 2008)
Carmichael v. Kellogg, Brown & Root Services, Inc.
572 F.3d 1271 (Eleventh Circuit, 2009)
TSC Industries, Inc. v. Northway, Inc.
426 U.S. 438 (Supreme Court, 1976)
Santa Fe Industries, Inc. v. Green
430 U.S. 462 (Supreme Court, 1977)
Basic Inc. v. Levinson
485 U.S. 224 (Supreme Court, 1988)
United States v. O'Hagan
521 U.S. 642 (Supreme Court, 1997)
Myers v. TOOJAY'S MANAGEMENT CORP.
640 F.3d 1278 (Eleventh Circuit, 2011)
FindWhat Investor Group v. FindWhat. Com
658 F.3d 1282 (Eleventh Circuit, 2011)
In Re Time Warner Inc. Securities Litigation
9 F.3d 259 (Second Circuit, 1993)
United States v. Armand P. D'AmAto
39 F.3d 1249 (Second Circuit, 1994)

Cite This Page — Counsel Stack

Bluebook (online)
Timothy Finnerty v. Stiefel Laboratories, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/timothy-finnerty-v-stiefel-laboratories-inc-ca11-2014.